{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"11.0","value":"10.4"},{"groupId":"OG001","lowerLimit":"13.0","upperLimit":"14.7","value":"13.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"337"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis","id":"OG000","title":"Paclitaxel and Carboplatin Chemotherapy"},{"description":"All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis","id":"OG001","title":"Paclitaxel and Carboplatin Chemotherapy With Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"All patients who were enrolled and eligible for the chemotherapy analysis (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).","reportingStatus":"POSTED","timeFrame":"Radiographic assessment of disease was conducted during chemotherapy and then every 6 months during the maintenance / surveillance phase","title":"Progression-free Survival (Chemotherapy Analysis)","type":"SECONDARY","unitOfMeasure":"Months"}